- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03173547
A Six Week Topical Cream Study for Subjects With Ichthyosis Vulgaris
A Randomized, Double-blind, Vehicle-controlled Study to Evaluate the Safety and Efficacy of 146-9251 Cream Applied Twice-daily for Six Weeks in Subjects With Ichthyosis Vulgaris
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
San Diego, California, United States, 92123
- Crown investigative site 01
-
-
Indiana
-
Plainfield, Indiana, United States, 46168
- Crown Investigative site 07
-
-
Louisiana
-
Metairie, Louisiana, United States, 70006
- Crown Investigative site 08
-
-
Minnesota
-
Fridley, Minnesota, United States, 55432
- Crown Investigative site 02
-
-
Missouri
-
Columbia, Missouri, United States, 65212
- Crown Investigative site 04
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87106
- Crown Investigative Site 05
-
-
North Carolina
-
High Point, North Carolina, United States, 27262
- Crown Investigative site 06
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject is a male or female and is at least 12 years old at the time of enrollment.
- Subject has provided written informed consent/assent. A subject under 18 years of age must provide written informed assent and be accompanied by the parent or legal guardian at the time of assent/consent signing. The parent or legal guardian must provide informed consent for the subject. If a subject becomes 18 years of age during the study, the subject must provide written informed consent at that time to continue study participation.
- Subject and parent/guardian (if applicable) are willing and able to apply the test article(s) as directed, comply with study instructions, and commit to all follow-up visits for the duration of the study.
- Subject has a clinical diagnosis of ichthyosis vulgaris involving a minimum of 5% body surface area (BSA). If the subject has IV involving over 40% BSA, the investigator must be able to identify a Treatment Area comprising distinct anatomic units that contains about 40% (excluding the scalp and mucosal areas) as detailed in Section 6.2.
- Subject has an Investigator's Global Assessment (IGA) score of at least three (3 = moderate) at the Baseline Visit.
- Subject is in good general health and free of any disease state or physical condition that might impair evaluation of IV or which, in the investigator's opinion, exposes the subject to an unacceptable risk by study participation.
- Females must be post-menopausal, surgically sterile, or use an effective method of birth control. , Women of childbearing potential (WOCBP) must have with a negative urine pregnancy test (UPT) at the Baseline Visit.
Exclusion Criteria:
1. Subject is pregnant, lactating, or is planning to become pregnant during the study.
2. Subject is currently enrolled in an investigational drug or device study. 3. Subject has used an investigational drug or investigational device treatment within 30 days prior to first application of the test article.
4. Subject has used any topical therapy, including topical corticosteroids or retinoids, in the Treatment Area within 2 weeks prior to the initiation of treatment. Note: a bland emollient may be used in the Treatment Area up to 3 days prior to the initiation of treatment.
5. Subject has used systemic corticosteroids within 4 weeks or retinoids within 24 weeks prior to the initiation of treatment.
6. Subject has stable use of vitamin or herbal supplements for less than 2 weeks prior to the initiation of treatment.
7. Subject has a history of sensitivity to any of the ingredients in the test articles.
8. Subject is known to be noncompliant or is unlikely to comply with the requirements of the study protocol (e.g., due to alcoholism, drug dependency, mental incapacity) in the opinion of the investigator.
9. Subject has a physical condition or other dermatologic disorders (e.g., atopic, seborrheic or contact dermatitis, psoriasis, tinea infections, etc.) which, in the investigator's opinion, might impair evaluation of IV, or which exposes the subject to unacceptable risk by study participation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 146-9251 cream
Topical cream to be applied two times daily to specified treatment areas for 6 weeks.
|
146-9251 cream contains an active drug and is applied topically.
|
Placebo Comparator: Vehicle cream
Topical cream to be applied two times daily to specified treatment areas for 6 weeks.
|
Vehicle cream does not contain an active drug and is applied topically.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment Success
Time Frame: Day 43 (6 weeks)
|
Number of participants that show at least a 2 level improvement of overall severity of disease (as measured by IGA score) at 6 weeks.
The IGA score is a static evaluation of the overall or "average" degree of severity of a participant's disease, taking into account all of the participant's scaling, erythema, and fissuring in the Treatment Area.
IGA was assessed using the following 5-point scale: clear (0), almost clear (1), mild (2), moderate (3), or severe (4).
|
Day 43 (6 weeks)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events (AEs)
Time Frame: Day 0 through study completion, average 6 weeks, Day 43.
|
AEs will be assessed by the investigator and the number of participants with any local and systemic AEs will be reported.
|
Day 0 through study completion, average 6 weeks, Day 43.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 146-9251-201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ichthyosis Vulgaris
-
University of AarhusUnknownComparison of Different Concentrations of Carbamide as Moisturizers in Ichthyosis Vulgaris (Urea-IV)Ichthyosis VulgarisDenmark
-
St. James's Hospital, IrelandUniversity of Dublin, Trinity College; Science Foundation IrelandRecruitingAtopic Dermatitis | Psoriasis Vulgaris | Ichthyosis VulgarisIreland
-
Northwestern UniversityViraCor LaboratoriesCompletedAtopic Dermatitis | Ichthyosis VulgarisUnited States
-
National Human Genome Research Institute (NHGRI)RecruitingEczema | Atopic Dermatitis | Ichthyosis VulgarisUnited States
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingAutosomal Recessive Congenital Ichthyosis | Epidermolytic IchthyosisFrance
-
Centre Hospitalier Universitaire de NiceUnknownLamellar IchthyosisFrance
-
Krystal Biotech, Inc.Not yet recruitingAutosomal Recessive IchthyosisUnited States
-
Krystal Biotech, Inc.Active, not recruitingTGM-1 Related Autosomal Recessive Congenital IchthyosisUnited States
-
Northwestern UniversityIcahn School of Medicine at Mount SinaiCompletedNetherton Syndrome | Ichthyosis | Lamellar Ichthyosis | Autosomal Recessive Congenital Ichthyosis | Congenital Ichthyosiform Erythroderma | Epidermolytic IchthyosisUnited States
-
Maastricht University Medical CenterRecruiting
Clinical Trials on 146-9251 cream
-
Stanford UniversityGE HealthcareRecruitingRadiculopathy | Neuropathic Pain | Myelopathy | Nociceptive Pain | Spinal Pain | Neurogenic Claudication | Mixed Pain (Nociceptive and Neuropathic)United States
-
Wayne State UniversityTerminatedPregnancyUnited States
-
Davidzon, Guido, M.D.Terminated
-
Stanford UniversityGE HealthcareEnrolling by invitationChronic Pain | Neuropathic Pain | Pediatric Disorder | Nociceptive PainUnited States
-
Guido A. Davidzon, MD, SMWithdrawn
-
Stanford UniversityActive, not recruiting
-
Stanford UniversityUniversity of Mississippi Medical CenterCompletedSciatica | Complex Regional Pain SyndromeUnited States
-
University of North Carolina, CharlotteTeva Branded Pharmaceutical Products R&D, Inc.CompletedMultiple SclerosisUnited States
-
Incyte CorporationCompletedCutaneous Lichen PlanusUnited States, Canada
-
Incyte CorporationRecruitingPrurigoUnited States, Spain, France, Poland, Germany, Belgium, Netherlands, Argentina, Italy, Canada, Chile, Brazil